MYGN Myriad Genetics, Inc.
$5.53
Myriad Genetics, Inc. (MYGN) Earnings News
Earnings press releases, previews and reviews for Myriad Genetics, Inc. (MYGN), newest first. Our most recent is review: Myriad Genetics Beats on a Pricing Rebound and Prenatal Exit, but Fading Volume Growth and Widening Losses Keep the Turnaround Unproven.
Wednesday
November 4, 2026
7:10 PM ET
Myriad Genetics Beats on a Pricing Rebound and Prenatal Exit, but Fading Volume Growth and Widening Losses Keep the Turnaround Unproven
Earnings Whispers · Review
Wednesday
November 4, 2026
4:05 PM ET
Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives
Tuesday
October 27, 2026
6:40 PM ET
Myriad Genetics Has Doubled Since Its Guidance Cut; Now Payer Pricing Must Stop Sliding
Earnings Whispers · Preview
Tuesday
October 20, 2026
8:30 AM ET
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
Thursday
October 15, 2026
4:05 PM ET
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
Thursday
July 30, 2026
4:05 PM ET
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
Thursday
July 23, 2026
9:05 AM ET
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026